GleamWall
中文EN

ABT ABBOTT LABORATORIES

Pharmaceutical Preparations · NYSE · SEC CIK 1800 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY10.0%
TTM net income YoY-66.4%
TTM EPS YoY-66.2%
Revenue 3-yr CAGR6.5%
Net income 3-yr CAGR-3.1%

Margins

Gross margin56.9%
Operating margin13.8%
Net margin9.7%
FCF margin14.0%
EBITDA margin17.0%

Returns

ROE9.2%
ROA4.9%
ROIC (approx.)7.1%
Asset turnover0.50x

Leverage & solvency

Liabilities / assets52.3%
Debt / equity0.61x
Current ratio1.45x
Interest coverage6.68x

Cash quality & payout

Operating cash flow / net income1.88x
Accruals ratio-4.3%
Payout ratio92.0%
Capex / revenue4.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$13.01B$12.59B$11.16B$11.46B$11.37B$11.14B$10.36B$10.97B
Cost of revenue$5.63B$5.33B$4.89B$4.92B$5.08B$4.85B$4.47B$4.94B
Gross profit$7.38B$7.27B$6.27B$6.54B$6.29B$6.29B$5.89B$6.03B
R&D expense$920.00M$892.00M$767.00M$735.00M$766.00M$725.00M$716.00M$749.00M
SG&A expense$4.27B$4.03B$3.74B$3.13B$3.05B$3.09B$3.06B$2.91B
Operating income$1.36B$1.69B$1.34B$2.25B$2.06B$2.05B$1.69B$1.91B
Interest expense$350.00M$351.00M$174.00M$120.00M$121.00M$121.00M$131.00M$136.00M
Pretax income$1.23B$1.52B$1.45B$2.36B$2.18B$2.15B$1.78B$2.03B
Income tax$311.00M$596.00M$372.00M$582.00M$536.00M$371.00M$453.00M-$7.20B
Net income$920.00M$928.00M$1.08B$1.78B$1.64B$1.78B$1.32B$9.23B
EBITDA$1.77B$2.10B$1.73B$2.62B$2.43B$2.41B$2.03B$2.25B
EPS (basic)0.530.530.62—0.941.020.76—
EPS (diluted)0.530.530.61—0.941.010.76—
Dividends declared per share0.630.630.630.630.590.590.590.59
Weighted avg. shares (diluted)1.74B1.74B1.75B—1.75B1.75B1.75B—
Balance sheet
Cash & equivalents$4.05B$5.10B$6.80B$8.52B$7.51B$6.95B$6.53B$7.62B
Short-term investments$246.00M$499.00M$492.00M$417.00M$222.00M$331.00M$312.00M$351.00M
Receivables$9.03B$8.60B$8.21B$7.93B$8.14B$7.97B$7.33B$6.92B
Inventory$7.34B$7.32B$6.99B$6.49B$6.71B$6.95B$6.64B$6.19B
Current assets$23.50B$24.52B$25.51B$26.00B$24.84B$24.47B$23.15B$23.66B
PP&E, net$12.88B$12.81B$12.38B$11.82B$11.50B$11.39B$10.93B$10.66B
Goodwill$32.64B$35.24B$35.22B$24.04B$23.97B$23.95B$23.36B$23.11B
Intangibles$19.59B$17.21B$17.88B$5.53B$5.60B$5.92B$6.26B$6.65B
Total assets$108.25B$109.22B$110.43B$86.71B$84.18B$84.00B$81.45B$81.41B
Current liabilities$16.15B$17.81B$18.38B$16.50B$14.58B$13.44B$13.00B$14.16B
Short-term debt$1.71B$3.00B$4.41B$3.03B$1.34B$507.00M$506.00M$1.50B
Long-term debt$29.45B$29.60B$29.64B$9.90B$11.60B$12.93B$12.74B$12.62B
Total debt$31.16B$32.61B$34.05B$12.93B$12.94B$13.44B$13.24B$14.12B
Total liabilities$56.62B$57.45B$57.73B$33.94B$32.92B$33.17B$32.38B$33.51B
Shareholders' equity$51.03B$51.11B$52.06B$52.13B$50.95B$50.56B$48.81B$47.66B
Net debt$27.11B$27.50B$27.24B$4.41B$5.43B$6.49B$6.71B$6.51B
Cash flow statement
Operating cash flow$1.74B$2.49B$1.31B$3.31B$2.79B$2.05B$1.42B$2.87B
Capital expenditure$513.00M$497.00M$399.00M$689.00M$496.00M$502.00M$484.00M$720.00M
Free cash flow$1.22B$1.99B$916.00M$2.63B$2.29B$1.54B$933.00M$2.15B
Investing cash flow-$385.00M-$673.00M-$20.32B-$913.00M-$457.00M-$582.00M-$470.00M-$866.00M
Financing cash flow-$2.40B-$3.52B$17.31B-$1.40B-$1.76B-$1.10B-$2.06B-$1.86B
Depreciation & amortization$415.00M$402.00M$381.00M$370.00M$371.00M$357.00M$336.00M$342.00M
Stock-based compensation$137.00M$168.00M$317.00M$113.00M$120.00M$142.00M$289.00M$111.00M
Dividends paid$1.09B$1.10B$1.10B$1.03B$1.03B$1.03B$1.03B$958.00M
Share buybacks$11.00M$1.04B$180.00M$302.00M$305.00M$6.00M$280.00M$315.00M

Free plan shows the latest 8 periods; Pro shows all 75 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.